Satisfaction and perceived effectiveness in patients on subcutaneous immunotherapy with a high-dose hypoallergenic pollen extract.
This study was designed to determine the level of satisfaction, tolerance and perceived effectiveness by patients in the first pollen season after starting treatment with Alergovit(®). For this purpose, a nationwide, retrospective, multicentre and cross-sectional observational study was carried on 256 patients. Perceived effectiveness by the patients was measured using a visual analogue scale and was clinically significant in 92.4% of the patients. The satisfaction level was evaluated with a specific questionnaire. 32.5% of the patients were totally satisfied with Allergovit(®) and 48.8% reported a high degree of satisfaction. The treatment was well tolerated by 99.2% of the patients. Our results demonstrate that subcutaneous immunotherapy with Allergovit(®) is effective and well-tolerated in routine clinical practice.
['Rodríguez Mosquera|M|M|', 'Sola Martínez|F J|FJ|', 'Montoro de Francisco|A|A|', 'Chivato Pérez|T|T|', 'Sánchez Moreno|V|V|', 'Rodríguez-Marco|A|A|', 'Hernández-Peña|J|J|']
D000293:Adolescent D000328:Adult D000485:Allergens D052179:Antigens, Plant D015415:Biomarkers D002648:Child D002675:Child, Preschool D003430:Cross-Sectional Studies D003888:Desensitization, Immunologic D005260:Female D006801:Humans D007073:Immunoglobulin E D008297:Male D008875:Middle Aged D017060:Patient Satisfaction D010465:Perception D012189:Retrospective Studies D006255:Rhinitis, Allergic, Seasonal D018570:Risk Assessment D012307:Risk Factors D013030:Spain D011795:Surveys and Questionnaires D016896:Treatment Outcome D014612:Vaccines D055815:Young Adult
perceived effectiveness effectiveness high-dose hypoallergenic Allergoid subcutaneous immunotherapy (SCIT)